Literature DB >> 32961017

Selective Affimers Recognise the BCL-2 Family Proteins BCL-xL and MCL-1 through Noncanonical Structural Motifs*.

Jennifer A Miles1,2,3, Fruzsina Hobor1,2, Chi H Trinh1,2, James Taylor1,2, Christian Tiede1,2, Philip R Rowell1,2, Brian R Jackson1,2,4, Fatima A Nadat1,2,4, Pallavi Ramsahye1,2, Hannah F Kyle1,2, Basile I M Wicky5, Jane Clarke5, Darren C Tomlinson1,2, Andrew J Wilson2,3, Thomas A Edwards1,2.   

Abstract

The BCL-2 family is a challenging group of proteins to target selectively due to sequence and structural homologies across the family. Selective ligands for the BCL-2 family regulators of apoptosis are useful as probes to understand cell biology and apoptotic signalling pathways, and as starting points for inhibitor design. We have used phage display to isolate Affimer reagents (non-antibody-binding proteins based on a conserved scaffold) to identify ligands for MCL-1, BCL-xL , BCL-2, BAK and BAX, then used multiple biophysical characterisation methods to probe the interactions. We established that purified Affimers elicit selective recognition of their target BCL-2 protein. For anti-apoptotic targets BCL-xL and MCL-1, competitive inhibition of their canonical protein-protein interactions is demonstrated. Co-crystal structures reveal an unprecedented mode of molecular recognition; where a BH3 helix is normally bound, flexible loops from the Affimer dock into the BH3 binding cleft. Moreover, the Affimers induce a change in the target proteins towards a desirable drug-bound-like conformation. These proof-of-concept studies indicate that Affimers could be used as alternative templates to inspire the design of selective BCL-2 family modulators and more generally other protein-protein interaction inhibitors.
© 2020 The Authors. Published by Wiley-VCH GmbH.

Entities:  

Keywords:  Affimers; BCL-2 family; chemical biology; non-antibody-binding proteins; protein-protein interactions

Year:  2020        PMID: 32961017      PMCID: PMC7821230          DOI: 10.1002/cbic.202000585

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  73 in total

1.  Exploration of the HIF-1α/p300 interface using peptide and Adhiron phage display technologies.

Authors:  Hannah F Kyle; Kate F Wickson; Jonathan Stott; George M Burslem; Alexander L Breeze; Christian Tiede; Darren C Tomlinson; Stuart L Warriner; Adam Nelson; Andrew J Wilson; Thomas A Edwards
Journal:  Mol Biosyst       Date:  2015-10

2.  Interfacing native and non-native peptides: using Affimers to recognise α-helix mimicking foldamers.

Authors:  Irene Arrata; Anna Barnard; Darren C Tomlinson; Andrew J Wilson
Journal:  Chem Commun (Camb)       Date:  2017-03-02       Impact factor: 6.222

Review 3.  Small-molecule inhibitors of protein-protein interactions: progressing toward the reality.

Authors:  Michelle R Arkin; Yinyan Tang; James A Wells
Journal:  Chem Biol       Date:  2014-09-18

4.  A potent and highly efficacious Bcl-2/Bcl-xL inhibitor.

Authors:  Angelo Aguilar; Haibin Zhou; Jianfang Chen; Liu Liu; Longchuan Bai; Donna McEachern; Chao-Yie Yang; Jennifer Meagher; Jeanne Stuckey; Shaomeng Wang
Journal:  J Med Chem       Date:  2013-03-22       Impact factor: 7.446

5.  Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix.

Authors:  Loren D Walensky; Andrew L Kung; Iris Escher; Thomas J Malia; Scott Barbuto; Renee D Wright; Gerhard Wagner; Gregory L Verdine; Stanley J Korsmeyer
Journal:  Science       Date:  2004-09-03       Impact factor: 47.728

6.  Allosteric nanobodies reveal the dynamic range and diverse mechanisms of G-protein-coupled receptor activation.

Authors:  Dean P Staus; Ryan T Strachan; Aashish Manglik; Biswaranjan Pani; Alem W Kahsai; Tae Hun Kim; Laura M Wingler; Seungkirl Ahn; Arnab Chatterjee; Ali Masoudi; Andrew C Kruse; Els Pardon; Jan Steyaert; William I Weis; R Scott Prosser; Brian K Kobilka; Tommaso Costa; Robert J Lefkowitz
Journal:  Nature       Date:  2016-07-13       Impact factor: 49.962

7.  Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).

Authors:  J D Leverson; H Zhang; J Chen; S K Tahir; D C Phillips; J Xue; P Nimmer; S Jin; M Smith; Y Xiao; P Kovar; A Tanaka; M Bruncko; G S Sheppard; L Wang; S Gierke; L Kategaya; D J Anderson; C Wong; J Eastham-Anderson; M J C Ludlam; D Sampath; W J Fairbrother; I Wertz; S H Rosenberg; C Tse; S W Elmore; A J Souers
Journal:  Cell Death Dis       Date:  2015-01-15       Impact factor: 8.469

Review 8.  Monobodies and other synthetic binding proteins for expanding protein science.

Authors:  Fern Sha; Gabriel Salzman; Ankit Gupta; Shohei Koide
Journal:  Protein Sci       Date:  2017-03-24       Impact factor: 6.725

9.  Stereocontrolled protein surface recognition using chiral oligoamide proteomimetic foldamers.

Authors:  Valeria Azzarito; Jennifer A Miles; Julie Fisher; Thomas A Edwards; Stuart L Warriner; Andrew J Wilson
Journal:  Chem Sci       Date:  2015-01-30       Impact factor: 9.825

10.  An interconnected hierarchical model of cell death regulation by the BCL-2 family.

Authors:  Hui-Chen Chen; Masayuki Kanai; Akane Inoue-Yamauchi; Ho-Chou Tu; Yafen Huang; Decheng Ren; Hyungjin Kim; Shugaku Takeda; Denis E Reyna; Po M Chan; Yogesh Tengarai Ganesan; Chung-Ping Liao; Evripidis Gavathiotis; James J Hsieh; Emily H Cheng
Journal:  Nat Cell Biol       Date:  2015-09-07       Impact factor: 28.824

View more
  3 in total

1.  RAS-inhibiting biologics identify and probe druggable pockets including an SII-α3 allosteric site.

Authors:  Katarzyna Z Haza; Heather L Martin; Ajinkya Rao; Amy L Turner; Sophie E Saunders; Britta Petersen; Christian Tiede; Kevin Tipping; Anna A Tang; Modupe Ajayi; Thomas Taylor; Maia Harvey; Keri M Fishwick; Thomas L Adams; Thembaninkosi G Gaule; Chi H Trinh; Matthew Johnson; Alexander L Breeze; Thomas A Edwards; Michael J McPherson; Darren C Tomlinson
Journal:  Nat Commun       Date:  2021-06-30       Impact factor: 14.919

2.  Selective Affimers Recognise the BCL-2 Family Proteins BCL-xL and MCL-1 through Noncanonical Structural Motifs*.

Authors:  Jennifer A Miles; Fruzsina Hobor; Chi H Trinh; James Taylor; Christian Tiede; Philip R Rowell; Brian R Jackson; Fatima A Nadat; Pallavi Ramsahye; Hannah F Kyle; Basile I M Wicky; Jane Clarke; Darren C Tomlinson; Andrew J Wilson; Thomas A Edwards
Journal:  Chembiochem       Date:  2020-11-02       Impact factor: 3.164

Review 3.  Mechanism of activation and the rewired network: New drug design concepts.

Authors:  Ruth Nussinov; Mingzhen Zhang; Ryan Maloney; Chung-Jung Tsai; Bengi Ruken Yavuz; Nurcan Tuncbag; Hyunbum Jang
Journal:  Med Res Rev       Date:  2021-10-25       Impact factor: 12.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.